


2022

**INTREPID HIV AND HCV GLOBAL MODEL AMONG PWID**


Estimated HIV incidence reductions and relative increase in cost of scale-up of ART, NSP, OAT\* compared to status quo

- Explore economic and population impact of interventions for PWID who are homeless, incarcerated, young, female, etc.



\*ART to 81% among HIV+ PWID, OAT to 40% among PWID, NSP to 100% receiving high coverage NSP (200 syringes/PWID/yr)

Challion A, Martin NK, et al. IAEN Conference 2022



**October 2022:** NIDA launches an ongoing [Seminar Series](#) offering improved access to cutting edge research at the intersection of HIV and substance use.

**October 2022:** The renewed NIDA HIV Working Group is launched; providing an opportunity for scientists across NIH to discuss initiatives and collaborations related to HIV and AIDS science.



**August 2022:** NIDA [issues](#) four new Funding Opportunity Announcements (FOAs) that are part of NIDA's Racial Equity Initiative, with goals that include promoting racial equity in NIDA's research portfolio.


2021




**December 2021:** On World AIDS Day, NIDA Director Dr. Nora D. Volkow issues a [statement](#) highlighting NIDA -funded innovations in HIV research, including the comprehensive [syringe services program](#) led by Avenir Award awardee Dr. Hansel E. Tookes, III.

▲ Image Courtesy NIDA/ Sonya Revell, Photographer

2021



**October 2021:** NIDA renames its AIDS Research Program the [NIDA HIV Research Program \(HRP\)](#) to reduce stigmatizing language, and to better reflect the evolving scientific focus on the virus itself and the intertwining epidemic of substance use disorders.





**June 2021:** NIDA issues a [Notice of Special Interest](#) in epidemiological investigations to quantify the impact of the coronavirus disease 2019 (COVID-19) pandemic on human immunodeficiency virus (HIV) prevention, incidence, transmission, and outcomes.



**February 2021:** [The Centers for Disease Control and Prevention lists HIV as a high-risk medical condition](#), and those patients should receive SARS-CoV-2 vaccines, regardless of CD4 or viral load, because the potential benefits outweigh potential risks.

2020




**December 2020:** On World AIDS Day 2020, NIDA Director Dr. Nora D. Volkow posts a [blog](#) highlighting the substantial strides in HIV research supported by NIDA over the past 3 decades.

2020



**November 2020:** In collaboration with NIMHD, NIDA issues two funding opportunities to [stimulate multi-level prevention](#) and [cost-effective care innovations](#) with a focus on highest risk and health disparities populations.



**July 2020:** NIDA Director Dr. Nora D. Volkow posts a [blog entry](#) on research at the intersection of HIV, COVID-19, and the opioid crisis.

**February 2020:** NIDA releases funding opportunity [“Implementing the HIV Service Cascade for Justice-Involved Populations”](#) to address research gaps related to integrated HIV and opioid use disorder services among justice-involved patients.

▲ Scanning electromicrograph of an HIV-infected T cell. Credit: NIAID

2019



**September 2019:** ARP Director Dr. Redonna K. Chandler presents updated NIDA HIV “High Priority” Research Areas to NIDA Council. (See 2:00:00 in [this videocast](#).)

**July 2019:** NIDA contributes to a [funding opportunity to stimulate research on interventions to reduce HIV-associated stigma](#) and its impact on prevention and treatment of HIV and on quality of life.



**July 2019:** NIDA Director Dr. Nora D. Volkow presents [“Opioid Use Disorders: Impact on HIV”](#) at the 2019 International AIDS Conference.

▲ Credit: International AIDS Society/Steve Forrest/Workers’ Photos

2018



- November 2018:** NIDA holds two [strategic planning workshops](#) to identify research gaps and opportunities for advancement of science at the intersection of HIV and substance use disorders.
- June 2018:** NIDA appoints [Dr. Vasundhara Varthakavi](#) as its first Associate Director for the NIDA AIDS Research Program.
- January 2018:** NIDA appoints [Dr. Redonna K. Chandler](#) as Director of the NIDA AIDS Research Program.

2015



- September 2015:** NIDA-funded scientists publish a [JAIDS special supplement](#) documenting how the burdens of HIV, drug use, and their co-occurring epidemics affect women in a global context.
- June 2015:** NIDA issues its first [Avenir Awards](#) to early-stage investigators proposing innovative research at the intersection of substance use and HIV.

2013



- April 2013:** NIDA Director Dr. Nora D. Volkow and ARP Director Dr. Jacques Normand [visit Vietnam](#) to foster research collaborations between NIDA and Vietnamese scientists on issues of HIV and drug use.
- November 2013:** NIDA-funded scientists publish a [special supplement outlining needs of people who inject drugs in central Asia](#), calling for quality surveillance and monitoring systems, as well as in-country implementation research.

▲ Credit: PEPFAR Vietnam

2012

**November 2012:** [Blog post](#) by NIDA Director Dr. Nora D. Volkow highlights HIV treatment disparities for people who inject drugs as an obstacle to achieving an AIDS-free generation.

2011



**February 2011:** NIDA issues a [funding opportunity announcement soliciting implementation science research to support PEPFAR](#) development of more efficient and cost-effective methods to deliver HIV prevention, treatment, and care for populations who use drugs.

2010



**November 2010:** NIDA releases [video interviews](#) with top scientists studying HIV in populations who use drugs from the 2010 International AIDS Conference.



**June 2010:** NIDA announces a funding opportunity encouraging the development and evaluation of [strategies to address HIV among vulnerable populations using seek, test, treat, and retain paradigms](#).

2009

**November 2009:** NIDA releases a funding opportunity for [interventions based on the seek, test, treat, and retain model to address HIV in the criminal justice system.](#)

2008

**September 2008:** NIDA issues its first [Avant-Garde Awards](#) to support creative scientists who propose high-impact research that will open new areas of HIV research related to drug use.



2007

**April 2007:** NIDA [launches A-START initiative](#) to expand drug use and HIV research funding opportunities for new and early career investigators.

**February 2007:** NIDA issues [new policy on HIV Education, Counseling, Testing, and Treatment for Research Subjects.](#)



2004

**Spring 2004:** NIDA establishes the AIDS Research Program (ARP) with Dr. Jacques Normand as its director.

